Sign in

Trial result ·

Intravenous Immunoglobulin Add-On in Newly Diagnosed Idiopathic Inflammatory Myopathies: A Randomized Clinical Trial.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This trial was in adults with newly found muscle disease, called IIMs. All of them took high doses of prednisone, the usual first drug. By chance, each person also got IVIG or a dummy treatment. IVIG is immune globulin given into a vein. They got it at weeks 0, 4 and 8. Neither people nor staff knew who got which. The main test was a combined muscle score at 12 weeks. In total, 44 adults took part at one expert center.

What they found

Of the 44 people, 42 reached the 12 week check. Of these, 23 got IVIG and 19 got the dummy. The average score was 60.0 with IVIG and 42.5 with the dummy. Higher scores mean more gain. Moderate gain was seen in 21 people on IVIG and 10 on dummy. Major gain was seen in 16 on IVIG and 5 on dummy. With IVIG, moderate gain came at a median of 4 weeks. With the dummy, it came at a median of 12 weeks. One person on IVIG had a deep vein clot without symptoms.

What it means for patients

The authors say adding IVIG to prednisone led to more gain. They also say the gain came faster than with prednisone alone. This was in adults whose disease had just been found. The abstract reports one blood clot in the IVIG group.

Why it is not certain yet

The trial had only 44 people, all at one center. Of 94 people checked, 50 did not join or were left out. The major gain result was looked at only after the trial. The abstract does not give results after 12 weeks.

Source

Intravenous Immunoglobulin Add-On in Newly Diagnosed Idiopathic Inflammatory Myopathies: A Randomized Clinical Trial.

PubMed · PMID 42734930

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Dermatomyositis and polymyositis (myositis) publications